Immunex Corp.'s two recent clinical setbacks could leave it with a weak middle in its product pipeline. The company discontinued a Phase II/III trial of its Enbrel etanercept in patients with chronic heart failure
Read the full 341 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury